People

Hans Schreiber, MD PhD

The main focus of this laboratory is to study the fundamental mechanisms that govern the interaction of cancer cells with the immune system. In particular, our laboratory is trying to exploit the fact that cancer cells usually carry cancer-specific mutations and antigens, and that under certain conditions, the immune system can destroy cancer cells even after they have disseminated in the body. We are trying to understand the mechanisms that often allow immunogenic cancer cells to escape immune destruction, and we want to develop new strategies and principles on which to base novel therapeutic approaches. We are also studying the signals needed for the immune system to be alerted be cancer cells, and then to destroy these cells. Finally, we combine immunology with genetics and biochemistry, which provides us with a powerful tool to search for cancer-specific changes in malignant cells in order to identify critical mechanisms and immunological targets that can be used to destroy the cancer.

The University of Chicago
Chicago
Ph.D
1977

Charite University Medicine
Berlin, Germany
Internship
1974

State of Baden-Wuerttemberg
Germany
Medical License
1974

Oak Ridge National Laboratory/Atomic Energy Comission, Biology Division
Post Doctoral - Experimental Carcinogenesis, Microbiology, and Cytology
1973

Educational Council for Foreign Medical Graduates
Diploma
1973

University of Freiburg
Germany
MD
1969

University of Freiburg
Germany
D.M.Sc. - Experimental Pathology, Radiation Biology
1969

Pritzer School of Medicine
Residency - Anatomic Pathology

Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell.
He Y, Schreiber K, Wolf SP, Wen F, Steentoft C, Zerweck J, Steiner M, Sharma P, Shepard HM, Posey A, June CH, Mandel U, Clausen H, Leisegang M, Meredith SC, Kranz DM, Schreiber H. Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell. JCI Insight. 2019 Dec 05; 4(23).
PMID: 31801912

Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell.
He Y, Schreiber K, Wolf SP, Wen F, Steentoft C, Zerweck J, Steiner M, Sharma P, Shepard HM, Posey A, June CH, Mandel U, Clausen H, Leisegang M, Meredith SC, Kranz DM, Schreiber H. Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell. JCI Insight. 2019 11 01; 4(21).
PMID: 31672936

Neoadjuvant PD-1 immune checkpoint blockade reverses functional immunodominance among tumor-antigen specific T cells.
Friedman J, Moore EC, Zolkind P, Robbins Y, Clavijo PE, Sun L, Greene S, Morisada MV, Mydlarz WK, Schmitt N, Hodge JW, Schreiber H, Van Waes C, Uppaluri R, Allen C. Neoadjuvant PD-1 immune checkpoint blockade reverses functional immunodominance among tumor-antigen specific T cells. Clin Cancer Res. 2019 Oct 23.
PMID: 31645352

TCR-pMHC bond conformation controls TCR ligand discrimination.
Sasmal DK, Feng W, Roy S, Leung P, He Y, Cai C, Cao G, Lian H, Qin J, Hui E, Schreiber H, Adams EJ, Huang J. TCR-pMHC bond conformation controls TCR ligand discrimination. Cell Mol Immunol. 2019 Sep 17.
PMID: 31530899

A strategy for generating cancer-specific monoclonal antibodies to aberrant O-glycoproteins: identification of a novel dysadherin-Tn antibody.
Steentoft C, Fuhrmann M, Battisti F, Van Coillie J, Madsen TD, Campos D, Halim A, Vakhrushev SY, Joshi HJ, Schreiber H, Mandel U, Narimatsu Y. A strategy for generating cancer-specific monoclonal antibodies to aberrant O-glycoproteins: identification of a novel dysadherin-Tn antibody. Glycobiology. 2019 04 01; 29(4):307-319.
PMID: 30726901

Fibroblasts: Dangerous travel companions.
Schreiber H. Fibroblasts: Dangerous travel companions. J Exp Med. 2019 Mar 04; 216(3):479-481.
PMID: 30710056

Tumour ischaemia by interferon-? resembles physiological blood vessel regression.
Kammertoens T, Friese C, Arina A, Idel C, Briesemeister D, Rothe M, Ivanov A, Szymborska A, Patone G, Kunz S, Sommermeyer D, Engels B, Leisegang M, Textor A, Fehling HJ, Fruttiger M, Lohoff M, Herrmann A, Yu H, Weichselbaum R, Uckert W, Hübner N, Gerhardt H, Beule D, Schreiber H, Blankenstein T. Tumour ischaemia by interferon-? resembles physiological blood vessel regression. Nature. 2017 05 04; 545(7652):98-102.
PMID: 28445461

Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.
Arina A, Karrison T, Galka E, Schreiber K, Weichselbaum RR, Schreiber H. Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication. Cancer Immunol Res. 2017 02; 5(2):127-136.
PMID: 28077434

Long-term Persistence of CD4+ but Rapid Disappearance of CD8+ T Cells Expressing an MHC Class I-restricted TCR of Nanomolar Affinity.
Engels B, Chervin AS, Sant AJ, Kranz DM, Schreiber H. Long-term Persistence of CD4+ but Rapid Disappearance of CD8+ T Cells Expressing an MHC Class I-restricted TCR of Nanomolar Affinity. Mol Ther. 2012 Mar; 20(3):652-660.
PMID: 28160633

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma.
Posey AD, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, Engels B, Stone JD, Madsen TD, Schreiber K, Haines KM, Cogdill AP, Chen TJ, Song D, Scholler J, Kranz DM, Feldman MD, Young R, Keith B, Schreiber H, Clausen H, Johnson LA, June CH. Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. Immunity. 2016 06 21; 44(6):1444-54.
PMID: 27332733

View All Publications